ArticleJournal of inflammation research2025
The Combined Diagnostic Value of Serum Trefoil Factor 2 and microRNA-186-5p for Evaluating Disease Severity in Patients with Acute Pancreatitis.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigated the association of serum Trefoil Factor 2 (TFF2) and microRNA-186-5p (miR-186-5p) levels with the severity and prognosis of acute pancreatitis (AP). Methods: A retrospective analysis was conducted on 380 AP patients, classified into mild to moderately severe (mild acute pancreatitis (MAP) and moderately severe acute pancreatitis (MSAP), n=205) and severe (SAP, n=175) groups. Serum TFF2 levels were measured by enzyme-linked immunosorbent assay (ELISA), and miR-186-5p expression was quantified via reverse transcription quantitative polymerase chain reaction (RT-qPCR). Correlations with inflammatory markers (high-sensitivity C-reactive protein (hs-CRP), interleukin-18 (IL-18), and tumor necrosis factor-α (TNF-α)) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were assessed using Pearson analysis. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves, and logistic regression was used to identify risk factors for SAP. Results: Compared with the MAP&MSAP group, the SAP group showed significantly elevated TFF2, hs-CRP, IL-18, TNF-α levels, and APACHE II scores, while miR-186-5p levels were significantly reduced (P < 0.05). TFF2 levels were positively correlated with inflammatory markers and APACHE II scores (r = 0.427-0.546), whereas miR-186-5p levels showed negative correlations (r = -0.431 to -0.570; all P < 0.05). TFF2 and miR-186-5p levels were inversely correlated (r = -0.483, P < 0.05). ROC analysis yielded AUCs of 0.804 for TFF2, 0.832 for miR-186-5p, and 0.895 for their combination in predicting SAP. Logistic regression identified TFF2 as an independent risk factor and miR-186-5p as a protective factor for SAP (P < 0.05). Conclusion: Elevated serum TFF2 level and reduced miR-186-5p level were found to be associated with increased AP severity. These biomarkers may serve as useful indicators for assessing disease severity and prognosis in AP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.